On September 2, Phreesia (NYSE:PHR) reported second-quarter fiscal 2027 results for the period ended July 31, showing revenue climbing to $129.5 million and adjusted EBITDA surging to $32.9 million. The healthcare technology company posted its fifth straight quarter of positive net income and its ninth straight quarter of positive operating cash flow, even as management flagged growing unpredictability in one of its core revenue lines. The quarter tells two stories at once: a business getting more efficient, and a client base under real financial pressure.
Profitability Finally Has Momentum
Revenue rose 10% year over year, with growth split between Network Solutions and Payment Solutions. Average healthcare services clients reached 4,744, up 6% from a year earlier, and total revenue per client climbed 4% to $27,289. The bigger story sits below the top line. Adjusted EBITDA jumped $10.8 million year over year to $32.9 million, pushing margin to 25%, while net income hit $1.9 million. Operating cash flow reached $18.3 million and free cash flow $13.8 million, gains of $3.5 million and $4.2 million, respectively.
That cash, combined with existing reserves, let Phreesia retire more than $23 million in debt principal during the quarter. Management also pointed to a May restructuring plan that eliminated 220 positions, about half of them contractor roles, at an estimated total cost of $10 million, of which $2.8 million was recognized this quarter. CEO Chaim Indig credited artificial intelligence with letting the company do things that were “just hard to imagine doing in a non-AI world,” particularly in testing and scaling new products.
On the growth side, the newer Provider Connect offering is gaining traction, and a four-month study in the GLP-1 category showed a 4% incremental lift in new-to-brand prescriptions and more than 1,000 new patient starts. Phreesia also expanded a securitization facility so its AccessOne financing arm can offer upfront funding to clients without investment-grade credit.
Cracks Beneath A Strained Client Base
The same call that delivered better margins also delivered a warning. CFO Balaji Gandhi said there is “now more variability in our network solutions revenue forecasting, particularly in the second half of each fiscal year,” a direct admission that visibility into that business has gotten murkier. Indig went further, describing healthcare providers as being “under a significant amount of strain” from shifting payer dynamics and broader economic pressure.
Management said it deliberately moderated subscription pricing to help those partners absorb rising costs, a choice that supports client retention but caps near-term pricing power. The numbers show some of that strain already. Total revenue per client fell about 2% sequentially, and total revenue itself dipped roughly 1% from the first quarter, both tied to seasonal declines in payment processing volume once health plan deductibles reset.
Phreesia’s cash balance slipped from $76.4 million to $74.6 million during the quarter, and the company still carries $61 million outstanding under its Capital One credit facility. None of this derailed the quarter, but it does mean the debt paydown and margin gains are happening against a backdrop of a client base that is not exactly flush.
Market Signals Stay Mixed
30 hedge funds held Phreesia shares in the most recent quarter, down slightly from 31 the quarter before, which points to modest trimming rather than a rush for the exits. Short interest sits at 5.80% of float, a level suggesting a real but not overwhelming bear camp. The stock trades at a forward P/E of 12.80, as of September 11, a multiple that assumes little of the margin expansion management just delivered. That combination suggests that the market has not fully credited the profitability turnaround yet.
Where The Story Goes From Here
Phreesia enters the back half of fiscal 2027 reaffirming both its $510 million to $520 million revenue outlook and its $125 million to $135 million adjusted EBITDA outlook, with AHSC growth expected in the mid-single digits. The bull case rests on continued EBITDA expansion, debt reduction, and new products like Provider Connect and AccessOne finding traction. The bear case rests on Gandhi’s own admission of reduced forecasting visibility, and Indig’s description of provider strain, both of which could pressure the very revenue lines guidance depends on.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
